However, the strong evidence that disease relapse due to drug resistance occurs shortly after initiation of BRAF inhibitor monotherapy, and that this is linked to the emergence of bypass mutations in resistant tumours which cause reactivation of the RAS/BRAF/MEK pathway [2], led to the development of dual therapies with BRAF and MEK inhibitors. The gene discussed is BRAF; the disease is neoplasm.